CTLA4 and neoplasm: By targeting immunosuppressive molecules such as PD-1/PD-L1 [27], CTLA-4 [28], TIM-3 [29], and NKG2A [30], or combining them with tumor-specific antigens, they can activate immune cells and enable them to effectively target the TME, resulting in specific tumor cell-killing effects.